ClinicalTrials.gg
CompletedNCT00333138Updated Sep 15, 2017Results posted

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

A Phase 2 interventional study of FTY720 and Placebo in Multiple Sclerosis, sponsored by Novartis. Completed at 26 sites in 11 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
12th of 34
281 · median 167
Started
2003
the only one that year
Phase 2
4 of 34
none open now
Registered
2nd of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 12th largest by enrollment, is the only one that started in 2003, is one of 4 in phase 2, and was the 2nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • FTY720
  • MS
  • Multiple Sclerosis
  • RRMS
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Core Study

Inclusion criteria

Inclusion Criteria:

  • Diagnosis of relapsing multiple Sclerosis (MS)
  • Patients with at least two documented relapses in the previous 2 years or one documented relapse in the last year
  • Patients with an Expanded Disability Status Scale (EDSS) score of 0-6

Extension Study

  • A positive Gd-enhanced MRI scan at screening (in case the first MRI scan obtained at screening was negative, a second scan could have been obtained 1 month later)
  • Neurologically stable with no evidence of relapse within 30 days prior to randomization,or during the Screening and Baseline periods.
  • Female patients either , surgically incapable of bearing children, or practicing an acceptable method of . Females of with a negative pregnancy test at baseline prior to entry into the treatment period.

Exclusion criteria

Exclusion Criteria:

Core Study

  • Patients with other chronic disease of the immune system, , pulmonary or heart disease, etc
  • Pregnant or nursing women

Extension Study

  • Patients who had permanently discontinued study drug prior to the Month 6 visit of the core study
  • Patients with diabetes mellitus (to reduce the risk of ME), and therefore ongoing patients with diabetes mellitus or who developed diabetes mellitus were discontinued from the study)

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    Fingolimod (FTY720) 1.25 mg/day

    Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.

    Drug: FTY720

  • Placebo comparator
    Placebo/Fingolimod (FTY720)

    Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.

    Drug: Placebo

  • Experimental
    Fingolimod (FTY720) 5.0 mg/day

    Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.

    Drug: FTY720

Interventions

  • DrugFTY720

    FTY720 capsule was taken orally once a day

  • DrugPlacebo

    Placebo 1.25 mg capsule was given once daily

06

What researchers measure

Primary outcomes

  1. Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)

    Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.

    Time frame: Month 6 (Core)

  2. Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12

    Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.

    Time frame: Month 12 (extension)

  3. Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60

    Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.

    Time frame: Month 60 (extension)

  4. Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study

    Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

    Time frame: Last observation (Up to 80 months in average)

Secondary outcomes

  1. Percentage of Participants Free of T1-weighted Lesions

    A patient was defined as free of lesions if s/he had zero lesions. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

    Time frame: Baseline, Months 6 (core), 12, 60 and Last Observation (up to 80 months in average)

  2. Percentage of Patients Free of Gd-enhanced T1-weighted and New T2- Weighted Lesions by Visit

    A patient was defined as free of lesions if s/he had zero lesions. The sum of all new T2-weighted lesions at Month 1 to last observation was zero (the sum is missing if one of the assessments was missing). New T2 lesions at a specific visit were assessed relative to the previous visit scan. Exception: new T2 lesions at Month 24 were assessed relative to Month 12. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

    Time frame: Month 6 and 12, 60, last observation (up to 80 months in average)

  3. Mean Number of New T2-weighted Lesions

    New T2 lesions at a specific visit were assessed relative to the previous visit scan. The total number of lesions (Month 1 to end of study) is calculated as the sum of the number of lesions at Months 1 to 6, Month 12, Month 60 and last observation. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

    Time frame: (Core) Month 6 and (Extension) 12, 60, last observation (up to 80 months in average)

  4. Volume of T2-weighted Lesions

    Volume of total T2-weighted lesions by visit were summarized. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

    Time frame: (Core) Month 6 and (Extension) 12, 60, last observation (up to 80 months in average)

  5. Change From Baseline in Volume of Total T2-weighted Lesions

    Change in volume of total T2-weighted lesions by visit were summarized. Negative values indicate improvement (reduction in lesion volume) and positive values worsening (increase in lesion volume). The last observation was the last observation available for each patient which ranged from 1 to 2801 days.

    Time frame: Baseline to month 6, 12, 60 and Last observation (up to 80 months in average)

  6. Time to Event Analysis: Kaplan Meier Estimates of Percentage of Relapse-free Patients

    The Expanded Disability Status Scale (EDSS) is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

    Time frame: Month 6,12,60 and Last observation (up to 80 months in average)

  7. Mean Trough Blood Concentrations of FTY720

    For each patient, the arithmetic mean of the two FTY720 trough blood levels from month 3 and 6 was calculated. This was taken as the patient's steady-state trough levels. Venous blood samples (3 mL) were collected before the dose in ethylenediaminetetraacetic acid (EDTA)-containing tubes at protocol-scheduled visits at months 3 and 6 in all patients.

    Time frame: Month 3 and 6

07

Results

Posted Oct 30, 2012

Participant flow

Core Study (6 Months)
Participant flow — Core Study (6 Months)
MilestonePlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Started939494
Completed868882
Not completed7612
Withdrew: Adverse event458
Withdrew: Withdrawal by subject112
Withdrew: Lack of efficacy100
Withdrew: Protocol violation101
Withdrew: Laboratory abnormality001
Extension Study (Month6 to End of Study)
Participant flow — Extension Study (Month6 to End of Study)
MilestonePlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Started838780
Completed404537
Not completed434243
Withdrew: Abnormal laboratory value322
Withdrew: Administrative problems112
Withdrew: Adverse event151915
Withdrew: Protocol violation003
Withdrew: Withdrawal by subject141314
Withdrew: Lack of efficacy747
Withdrew: Patient no longer required study drug210
Withdrew: Lost to follow-up110
Withdrew: Death010

Outcome measures

PrimaryMean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)

Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.

Time frame:
Month 6 (Core)
Reported as:
Mean · GD- enhanced T1 lesions
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)
GD- enhanced T1 lesionsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)2.3 ± 4.231.4 ± 5.690.4 ± 0.82
SecondaryPercentage of Participants Free of T1-weighted Lesions

A patient was defined as free of lesions if s/he had zero lesions. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

Time frame:
Baseline, Months 6 (core), 12, 60 and Last Observation (up to 80 months in average)
Reported as:
Number · percentage of participants
Percentage of Participants Free of T1-weighted Lesions
percentage of participantsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Baseline (Core) n=93, 92, 9349.552.248.4
Month 6 (Core) n= 83, 90, 8747.076.778.2
Month 12 (Extension) n= 72, 77, 7179.283.188.7
Month 60 (Extension) n= 45, 49, 4491.191.893.2
Last observation (Extension) n= 92, 93, 9281.583.983.7
PrimaryMean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12

Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.

Time frame:
Month 12 (extension)
Reported as:
Mean · GD- enhanced T1 lesions
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12
GD- enhanced T1 lesionsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 120.4 ± 0.951.0 ± 5.810.2 ± 0.47
PrimaryMean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60

Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.

Time frame:
Month 60 (extension)
Reported as:
Mean · GD- enhanced T1 lesions
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60
GD- enhanced T1 lesionsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 600.2 ± 0.70.2 ± 0.920.1 ± 0.55
PrimaryMean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study

Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

Time frame:
Last observation (Up to 80 months in average)
Reported as:
Mean · GD- enhanced T1 lesions
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study
GD- enhanced T1 lesionsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study0.8 ± 2.870.4 ± 1.390.5 ± 1.65
SecondaryPercentage of Patients Free of Gd-enhanced T1-weighted and New T2- Weighted Lesions by Visit

A patient was defined as free of lesions if s/he had zero lesions. The sum of all new T2-weighted lesions at Month 1 to last observation was zero (the sum is missing if one of the assessments was missing). New T2 lesions at a specific visit were assessed relative to the previous visit scan. Exception: new T2 lesions at Month 24 were assessed relative to Month 12. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

Time frame:
Month 6 and 12, 60, last observation (up to 80 months in average)
Reported as:
Number · percentage of paticipants
Percentage of Patients Free of Gd-enhanced T1-weighted and New T2- Weighted Lesions by Visit
percentage of paticipantsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Month 6 (Core), n= 80, 87, 8347.577.080.7
Month 12 (Extension) n=70, 77, 7057.167.572.9
Month 60 (Extension) n=45, 49, 4388.987.883.7
Last observation (Extension) n=92, 93,9072.876.378.9
SecondaryMean Number of New T2-weighted Lesions

New T2 lesions at a specific visit were assessed relative to the previous visit scan. The total number of lesions (Month 1 to end of study) is calculated as the sum of the number of lesions at Months 1 to 6, Month 12, Month 60 and last observation. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

Time frame:
(Core) Month 6 and (Extension) 12, 60, last observation (up to 80 months in average)
Reported as:
Mean · GD enhanced T2 lesions
Mean Number of New T2-weighted Lesions
GD enhanced T2 lesionsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Month 6 (Core), n= 82,88, 841.0 ± 2.370.5 ± 2.070.1 ± 0.34
Month 12 (Extension) n=71, 79, 710.8 ± 1.411.4 ± 5.560.6 ± 1.10
Month 60 (Extension) n=45, 50, 430.4 ± 1.250.5 ± 1.360.3 ± 0.97
Last observation (Extension) n=92, 93, 910.7 ± 1.990.6 ± 1.510.5 ± 1.64
SecondaryVolume of T2-weighted Lesions

Volume of total T2-weighted lesions by visit were summarized. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

Time frame:
(Core) Month 6 and (Extension) 12, 60, last observation (up to 80 months in average)
Reported as:
Mean · mm^3
Volume of T2-weighted Lesions
mm^3PlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Month 6 (Core) n=85, 91, 879016.0 ± 10361.8310084.6 ± 14774.168331.1 ± 10162.01
Month 12 (Extension) n= 73, 79, 728264.1 ± 10121.4310707.1 ± 14887.668363.2 ± 10694.82
Month 60 (Extension) n=45, 50, 446698.3 ± 9569.989498.7 ± 9765.606626.9 ± 9146.01
Last observation (Extension) n=87, 91, 888757.2 ± 10127.0110090.2 ± 13999.508061.8 ± 9003.47
SecondaryChange From Baseline in Volume of Total T2-weighted Lesions

Change in volume of total T2-weighted lesions by visit were summarized. Negative values indicate improvement (reduction in lesion volume) and positive values worsening (increase in lesion volume). The last observation was the last observation available for each patient which ranged from 1 to 2801 days.

Time frame:
Baseline to month 6, 12, 60 and Last observation (up to 80 months in average)
Reported as:
Mean · mm^3
Change From Baseline in Volume of Total T2-weighted Lesions
mm^3PlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
Month 6 (core) n=85, 89, 86146.15 ± 1683.602-115.81 ± 1031.799-607.97 ± 1705.486
Month 12 (extension) n=73, 77, 71144.96 ± 1513.5771.66 ± 1714.731-513.35 ± 1943.338
Month 60 (extension) n=45, 49, 43-621.82 ± 1338.966-204.09 ± 2238.182-1429.98 ± 3928.944
Last observation (extension) n= 87, 89, 87-178.86 ± 1884.904-92.24 ± 3033.041-907.48 ± 2997.668
SecondaryTime to Event Analysis: Kaplan Meier Estimates of Percentage of Relapse-free Patients

The Expanded Disability Status Scale (EDSS) is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method. The last observation was the last observation available for each patient which ranged from 1 to 2801 days

Time frame:
Month 6,12,60 and Last observation (up to 80 months in average)
Reported as:
Number · percentage of participants
Time to Event Analysis: Kaplan Meier Estimates of Percentage of Relapse-free Patients
percentage of participantsPlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/Day
0 days (n=93,94,94)1.00 (1.000 to 1.000)1.00 (1.000 to 1.000)1.00 (1.000 to 1.000)
200 days (n=57, 73, 70)0.69 (0.589 to 0.782)0.86 (0.786 to 0.929)0.86 (0.782 to 0.928)
400 days (n=48, 63, 60)0.62 (0.520 to 0.725)0.78 (0.699 to 0.871)0.79 (0.707 to 0.878)
600 days (n=41, 57, 52)0.58 (0.478 to 0.688)0.76 (0.669 to 0.849)0.78 (0.690 to 0.867)
800 days (n=38, 48, 48)0.55 (0.477 to 0.662)0.75 (0.652 to 0.838)0.75 (0.653 to 0.843)
1000 days (n=35, 42, 45)0.53 (0.416 to 0.634)0.70 (0.595 to 0.798)0.75 (0.653 to 0.843)
1200 days (n=30, 38 40)0.51 (0.399 to 0.619)0.66 (0.55 to 0.770)0.70 (0.594 to 0.802)
1400 days (n=29, 36, 35)0.51 (0.399 to 0.619)0.63 (0.516 to 0.739)0.70 (0.594 to 0.802)
1600 days (n=27, 34, 34)0.51 (0.399 to 0.619)0.61 (0.496 to 0.724)0.68 (0.570 to 0.786)
1800 days (n=25, 33, 33)0.51 (0.399 to 0.619)0.61 (0.496 to 0.724)0.68 (0.570 to 0.786)
2000 days (n=23, 31, 31)0.51 (0.399 to 0.619)0.59 (0.475 to 0.707)0.66 (0.545 to 0.769)
2200 days (n=22, 28, 30)0.49 (0.373 to 0.600)0.55 (0.433 to 0.673)0.66 (0.545 to 0.769)
2400 days (n=21, 26, 27)0.46 (0.348 to 0.581)0.55 (0.433 to 0.673)0.66 (0.545 to 0.769)
2600 days (n=9, 12, 12)0.44 (0.313 to 0.558)0.55 (0.433 to 0.673)0.66 (0.545 to 0.769)
2880 days (n=0, 0, 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
SecondaryMean Trough Blood Concentrations of FTY720

For each patient, the arithmetic mean of the two FTY720 trough blood levels from month 3 and 6 was calculated. This was taken as the patient's steady-state trough levels. Venous blood samples (3 mL) were collected before the dose in ethylenediaminetetraacetic acid (EDTA)-containing tubes at protocol-scheduled visits at months 3 and 6 in all patients.

Time frame:
Month 3 and 6
Reported as:
Mean · ng/mL
Mean Trough Blood Concentrations of FTY720
ng/mLFTY720 1.25 mg/DayFTY720 5.0 mg/Day
Month 3 (core)7.64 ± 5.4430.5 ± 18.8
Month 6 (core)7.38 ± 4.5728.9 ± 22.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—25/93 (26.9%)86/93 (92.5%)
Fingolimod (FTY720) 1.25 mg—19/94 (20.2%)88/94 (93.6%)
Fingolimod (FTY720) 5.0 mg—32/94 (34%)92/94 (97.9%)
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventPlaceboFingolimod (FTY720) 1.25 mgFingolimod (FTY720) 5.0 mg
BradycardiaCardiac disorders1/930/943/94
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/931/943/94
Macular oedemaEye disorders0/932/942/94
Chest painGeneral disorders0/931/942/94
CholelithiasisHepatobiliary disorders0/932/940/94
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/930/942/94
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/932/940/94
AnxietyPsychiatric disorders0/932/940/94
AsthmaRespiratory, thoracic and mediastinal disorders0/930/942/94
ThrombocytopeniaBlood and lymphatic system disorders1/930/940/94
Most frequent other events
Showing 10 of 82
Most frequent other events
EventPlaceboFingolimod (FTY720) 1.25 mgFingolimod (FTY720) 5.0 mg
NasopharyngitisInfections and infestations34/9339/9442/94
HeadacheNervous system disorders28/9335/9425/94
FatigueGeneral disorders22/9323/9416/94
InfluenzaInfections and infestations16/9323/9422/94
Back painMusculoskeletal and connective tissue disorders22/9316/9419/94
Upper respiratory tract infectionInfections and infestations19/9319/9418/94
CoughRespiratory, thoracic and mediastinal disorders12/9316/9419/94
HypertensionVascular disorders13/9319/9410/94
Alanine aminotransferase increasedInvestigations18/9312/9415/94
Pain in extremityMusculoskeletal and connective tissue disorders18/9315/9415/94

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/DayTotal
Mean37.0 ± 8.8038.1 ± 9.5438.3 ± 10.5137.8 ± 9.63
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFingolimod (FTY720) 1.25 mg/DayFingolimod (FTY720) 5.0 mg/DayTotal
Female627166199
Male31232882
08

Study locations

26 sites
  • Novartis Investigational site
    Montreal, Canada
  • Novartis Investigational site
    Ottawa, Canada
  • Novartis Investigational site
    Toronto, Canada
  • Novartis Investigational site
    Vancouver, Canada
  • Novartis Investigational site
    Copenhagen, Denmark
  • Novartis Investigational site
    Helsinki, Finland
  • Novartis Investigational site
    Turku, Finland
  • Novartis Investigational site
    Lille, France
  • Novartis Investigational site
    Marseille, France
  • Novartis Investigational site
    Schwendi, Germany
  • Novartis Investigational site
    Wurzburg, Germany
  • Novartis Investigational site
    Gallarate, Italy
  • Novartis Investigational site
    Genova, Italy
  • Novartis Investigational site
    Milano, Italy
  • Novartis Investigational site
    Roma, Italy
  • Novartis Investigational site
    Warszawa, Poland
  • Novartis Investigational site
    Coimbra, Portugal
  • Novartis Investigational site
    Lisboa, Portugal
  • Novartis Investigational site
    Barcelona, Spain
  • Novartis Investigational site
    Madrid, Spain
  • Novartis Investigational site
    Malaga, Spain
  • Novartis Investigational site
    Sevilla, Spain
  • Novartis Investigational site
    Valencia, Spain
  • Novartis Investigational site
    Basel, Switzerland
  • Novartis Investigational site
    Zurich, Switzerland
  • Novartis Investigational site
    Newcastle upon Tyne, United Kingdom
09

References and documents

Publications

  • Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24. PubMed 23531349 ↗
  • Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643. PubMed 16971719 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2006
First posted
Jun 2, 2006
Start
May 2003
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Oct 30, 2012
Last update
Sep 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00333138
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jun 2, 2006
Start date
May 2003
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Oct 30, 2012
Last update
Sep 15, 2017

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion